GlaxoSmithKline hopes to complete testing by year's end to confirm whether the drug is effective against all the various mutations seen with the variant.
Patents are just one part of the vaccine puzzle. The key is the know-how about the actual manufacturing process.
Delays in sharing clinical trial data is one of the key reasons behind skepticism.
The development of Covid-19 vaccines in record time will not be enough to fix big pharma’s tarnished image.
The two companies said they planned to launch another study next year, hoping to come up with a more effective vaccine by the end of 2021.
Initial vaccine tests focus on safety, and researchers in both countries are trying out different doses of different types of shots. Second phase allows vaccines to be tested to look for signs that they protect against infection.
GSK said it would have a 68-percent controlling equity interest in the joint venture that will have combined sales of about $13 billion.
British drugmaker GlaxoSmithKline developed the injectable vaccine to protect children from the most deadly form of malaria in Africa.
Subscribe to our Youtube channel for all latest in-depth, on the ground reporting from around the world.
Copyright © 2022 TRT World.